Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings.

Anastasios E SepetisHolly ClarkeBhaskar Gupta

Published in: International journal of retina and vitreous (2022)

We provide real world data suggesting a sustained anatomical and functional benefit of switching from ranibizumab to aflibercept in the treatment of refractory DMO.

Keyphrases

age related macular degeneration
diabetic retinopathy
type diabetes
electronic health record
combination therapy
machine learning
replacement therapy
smoking cessation